Cargando…

P1101: A PROSPECTIVE TRIAL OF A NOVEL RECOMBINANT HUMANIZEDANTI-INTERLEUKIN-6 RECEPTOR MONOCLONAL ANTIBODY INJECTION(VDJ001) IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: THE PRELIMINARY RESULTS

Detalles Bibliográficos
Autores principales:	Zhang, Lu, Dong, Yujun, Gong, Xiao-Ming, Zhang, Xiao-Rui, MA, Rong, Cheng, Jian-Wei, Zhang, Jun, LI, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430902/ http://dx.doi.org/10.1097/01.HS9.0000971300.41514.8a

Ejemplares similares

Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody
por: Tomioka, Yasuaki, et al.
Publicado: (2021)

Candidate biomarkers for idiopathic multicentric Castleman disease
por: Sumiyoshi, Remi, et al.
Publicado: (2022)

Alveolar Hemorrhage in Idiopathic Multicentric Castleman’s Disease
por: Huang, Lingtong, et al.
Publicado: (2023)

VDJ Recombination: Artemis and Its In Vivo Role in Hairpin Opening
por: Mansilla-Soto, Jorge, et al.
Publicado: (2003)

Individualized VDJ recombination predisposes the available Ig sequence space
por: Slabodkin, Andrei, et al.
Publicado: (2021)

Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports
por: Ferrero, Simone, et al.
Publicado: (2021)

Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura
por: Sood, Ruchi, et al.
Publicado: (2013)

Idiopathic Multicentric Hyaline Vascular-Type Castleman Disease
por: Moutinho, Adelaide, et al.
Publicado: (2021)

Developmental Regulation of VDJ Recombination By the Core Fragment of the T Cell Receptor α Enhancer
por: Roberts, Joseph L., et al.
Publicado: (1997)

Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease
por: Nishikori, Asami, et al.
Publicado: (2022)

Idiopathic Multicentric Castleman Disease with Cutaneous Manifestation: Case Report
por: Kosmidis, Christoforos S., et al.
Publicado: (2022)

The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease
por: Horna, Pedro, et al.
Publicado: (2022)

TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy
por: Williams, Corinne, et al.
Publicado: (2021)

A Rare Variant of Idiopathic Multicentric Castleman Disease: TAFRO Syndrome
por: Ük, Ece, et al.
Publicado: (2022)

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
por: Pierson, Sheila K., et al.
Publicado: (2022)

Radiological and Pathological Features of Cyst Formation in Idiopathic Multicentric Castleman Disease
por: Otoshi, Ryota, et al.
Publicado: (2023)

Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab
por: Aita, Tetsuro, et al.
Publicado: (2020)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Cutaneous plasmacytosis: A rare initial presentation of idiopathic multicentric Castleman's disease
por: Yamamoto, Yu, et al.
Publicado: (2021)

Idiopathic Multicentric Castleman Disease Presenting With Hypertensive Choroidopathy: A Case Report
por: Mimoto, Tamami, et al.
Publicado: (2023)

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022)

Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
por: Pierson, Sheila K., et al.
Publicado: (2023)

PDK1 regulates VDJ recombination, cell-cycle exit and survival during B-cell development
por: Venigalla, Ram K C, et al.
Publicado: (2013)

Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report
por: Yuan, Zhen-gang, et al.
Publicado: (2009)

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021)

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report
por: Lang, Evan, et al.
Publicado: (2022)

Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?
por: Nishimura, Yoshito, et al.
Publicado: (2022)

Systemic lupus erythematosus mimicking idiopathic multicentric Castleman disease: A diagnostic dilemma
por: Gunathilake, KUIS, et al.
Publicado: (2022)

Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis
por: González García, Andrés, et al.
Publicado: (2022)

HIV-associated multicentric Castleman's disease
por: Naime, Fauzia de Fátima, et al.
Publicado: (2012)

Multicentric Castleman disease and the evolution of the concept
por: Zhou, Ting, et al.
Publicado: (2021)

A Hands-On Activity to Demonstrate the Central Dogma of Molecular Biology Via a Simulated VDJ Recombination Activity
por: Marshall, Pamela A.
Publicado: (2017)

Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease
por: Li, Feng, et al.
Publicado: (2018)

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2015)

Idiopathic multicentric Castleman disease with pulmonary and cutaneous lesions treated with tocilizumab: A case report
por: Han, Ping-Yang, et al.
Publicado: (2020)

Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease
por: Arakawa, Akira, et al.
Publicado: (2021)

Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) AS A MANIFESTATION OF POST-COVID-19 INFLAMMATORY SYNDROME
por: YAN, CHRIS, et al.
Publicado: (2022)

Multicentric Castleman's disease: a case report
por: Menezes, Brian F, et al.
Publicado: (2007)

Multicentric Castleman's disease: Report of three cases
por: Guazzaroni, M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mp6ulkn2sbd0s26ljptnfe45tv